|
 |
|
 |
 |
 |
|
Stock Quote (NASDAQ: DNDN)
Price:
3.94
Change:
- 0.07
Volume:
3,260,000
4:00 PM ET on May 20, 2013
Delayed at least 20 minutes.
Provided by eSignal. |
|
Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.
Recent ReleasesMay 9, 2013
Dendreon Announces First Quarter 2013 Results
May 6, 2013
PROVENGE® (sipuleucel-T) Data Presented at An Annual Scientific Urology Meeting
Apr 24, 2013
Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial Results
May 30, 2013 at 10:40 AM ET
Deutsche Bank Securities 38th Annual dbAccess Health Care Conference
May 14, 2013 at 1:40 PM PT
Bank of America Merrill Lynch 2013 Health Care Conference
| MEDCAC 11.17.10 Presentation |
|
397.5 KB |
| Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) |
|
421.1 KB |
Investor Relations |
Media |
Delicious
Digg
Facebook
LinkedIn
Twitter